Does Cyp3a Inducers Interact with Crinecerfont?
Cyp3a Inducers and Crinecerfont have a moderate drug interaction according to U.S. FDA drug labeling data. Concomitant use decreases crinecerfont exposure, which may reduce efficacy. Requires 2-fold increase in morning and evening dosage. The mechanism involves crenessity is a cyp3a4 substrate; inducers decrease its exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Crinecerfont Class
- Corticotropin-releasing Factor Type 1 Receptor Antagonist
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Cyp3a Inducers and Crinecerfont occurs because crenessity is a cyp3a4 substrate; inducers decrease its exposure. Clinically, this means concomitant use decreases crinecerfont exposure, which may reduce efficacy. requires 2-fold increase in morning and evening dosage. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Cyp3a Inducers and your doctor is considering prescribing Crinecerfont (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider